(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
